Compare IMUX & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | KINS |
|---|---|---|
| Founded | 2016 | 1886 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.8M | 205.7M |
| IPO Year | 2013 | 2013 |
| Metric | IMUX | KINS |
|---|---|---|
| Price | $14.17 | $16.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 232.3K | 83.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | 38.00 | ★ 94.59 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | N/A | $24.23 |
| Revenue Next Year | N/A | $18.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $0.51 | $13.08 |
| 52 Week High | $15.77 | $19.42 |
| Indicator | IMUX | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 62.56 | 57.08 |
| Support Level | $0.74 | $14.17 |
| Resistance Level | $15.77 | $16.73 |
| Average True Range (ATR) | 1.18 | 0.47 |
| MACD | -0.21 | 0.10 |
| Stochastic Oscillator | 69.09 | 81.07 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.